Takeda’s Takhzyro (lanadelumab injection) Receives CADTH’s CDEC Positive Opinion for the Routine Prevention of Hereditary Angioedema Attacks

 Takeda’s Takhzyro (lanadelumab injection) Receives CADTH’s CDEC Positive Opinion for the Routine Prevention of Hereditary Angioedema Attacks

Takeda’s Takhzyro (lanadelumab injection) Receives CADTH’s CDEC Positive Opinion for the Routine Prevention of Hereditary Angioedema Attacks

Shots:

  • The positive recommendation is based on P-III Help Study Open-label Extension assessing Takhzyro (300mg, q2w) in 212 HAE adolescents and adults aged ≥12 yrs.
  • The P-III Help study OLE results: reduction rate of attacks, reduction in attacks requiring acute treatment (92.6%), reduction in mod. to sev. attacks (83.6%), mean attack rate (87%); 58% & 78% patients showed maximum attack-free period lasted ≥12mos. & ≥6mos. following the first regular treatment dose respectively
  • Takhzyro is a mAb targeting plasma kallikrein activity, indicated for the routine prevention of HAE attacks in patients aged ≥12 yrs. and is an approved therapy in multiple countries including the US, EU, Australia and Switzerland with additional ongoing regulatory submission across the globe

Click here to­ read full press release/ article | Ref: Newswire Canada  | Image: The Display Builder

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post